Abstract:Author summary Multiple members in a family can be diagnosed with the same disease. In such families, genetics may be a significant factor in disease risk. However, it remains unclear whether such familial aggregation of disease is likely due to a single highly penetrant rare variant (HPRV), many minimally penetrant common variants, or a combination of the two types of variants. We therefore use recent estimates of SNP heritability and the liability threshold model to estimate the proportion of afflicted families likely to carry a rare, causal variant. We then show that Polygenic Risk Scores (PRS) may be useful for identifying families likely to carry such a rare variant and introduce a related statistic that can be used to select families for sequencing studies trying to identify HPRV. Despite genetics being accepted as the primary cause of familial aggregation for most diseases, it is still unclear whether afflicted families are likely to share a single highly penetrant rare variant, many minimally penetrant common variants, or a combination of the two types of variants. We therefore use recent estimates of SNP heritability and the liability threshold model to estimate the proportion of afflicted families likely to carry a rare, causal variant. We then show that Polygenic Risk Scores (PRS) may be useful for identifying families likely to carry such a rare variant and therefore for prioritizing families to include in sequencing studies with that aim. Specifically, we introduce a new statistic that estimates the proportion of individuals carrying causal rare variants based on the family structure, disease pattern, and PRS of genotyped individuals. Finally, we consider data from the MelaNostrum consortium and show that, despite an estimated PRS heritability of only 0.05 for melanoma, families carrying putative causal variants had a statistically significantly lower PRS, supporting the idea that PRS prioritization may be a useful future tool. However, it will be important to evaluate whether the presence of rare mendelian variants are generally associated with the proposed test statistic or lower PRS in future and larger studies.

Rare penetrant mutations confer severe risk of common diseases

Complex trait associations in rare diseases and impacts on Mendelian variant interpretation

The celebration of the 20th anniversary of WORK.

Common genetic variants contribute to risk of rare severe neurodevelopmental disorders

Rare and low-frequency variants in human common diseases and other complex traits

Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Unique roles of rare variants in the genetics of complex diseases in humans

Polygenic architecture of rare coding variation across 394,783 exomes

Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies.

Integration of Rare Large-Effect Expression Variants Improves Polygenic Risk Prediction

Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes

Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases

Genetic associations of protein-coding variants in human disease

Exploring penetrance of clinically relevant variants in over 800,000 humans from the Genome Aggregation Database

A polygenic burden of rare disruptive mutations in schizophrenia

Investigating the role of common cis-regulatory variants in modifying penetrance of putatively damaging, inherited variants in severe neurodevelopmental disorders

Functional dissection of complex and molecular trait variants at single nucleotide resolution

Dissecting the contribution of common variants to risk of rare neurodevelopmental conditions

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

A Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in Lung Cancer